Advertisement

Topics

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors

2014-08-27 03:17:56 | BioPortfolio

Summary

This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore EMD 1214063, in patients with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.

Subjects will be assigned to one of two dosing regimens:

- Regimen 1: EMD 1214063 every day for 14 days, followed by seven days with no treatment (21-day cycle)

- Regimen 2: EMD 1214063 three times per week (e.g., Days 1, 3, and 5) for three weeks (21-day cycle)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Intervention

EMD 1214063, EMD 1214063

Location

M.D. Anderson Cancer Center
Houston
Texas
United States

Status

Recruiting

Source

EMD Serono

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:17:56-0400

Clinical Trials [3229 Associated Clinical Trials listed on BioPortfolio]

A Study of QBI-139 in Subjects With Advanced Solid Tumors

The purposes of this trial are: - To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors. - To determine the maximum tole...

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblasto...

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS)...

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Phase I Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus in Patients With Refractory Solid Tumors

This is a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of intratumoral administration of VSV-IFNβ-NIS in patients with refractory advanced/metastatic ...

PubMed Articles [28953 Associated PubMed Articles listed on BioPortfolio]

A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.

This phase 1/2 study (NCT01751308) evaluated cabazitaxel in pediatric patients. Phase 1 determined the maximum tolerated dose (MTD) in patients with recurrent/refractory solid tumors, including centra...

Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.

Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has be...

Prognostic value of DcR3 in solid tumors: A meta-analysis.

Decoy receptor 3 (DcR3) has been reported to be overexpressed in a wide range of solid tumors, suggesting that DcR3 plays a crucial role in the development and progression of cancer. The present meta-...

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with...

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.

Background: Blockade of programmed death 1 (PD-1), an inhibitory T lymphocyte receptor, is associated with immune system enhancement and tumor remission in various tumors. We assessed the anti-tumor a...

Medical and Biotech [MESH] Definitions

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

Procedures using an electrically heated wire or scalpel to treat hemorrhage (e.g., bleeding ulcers) and to ablate tumors, mucosal lesions, and refractory arrhythmias. It is different from ELECTROSURGERY which is used more for cutting tissue than destroying and in which the patient is part of the electric circuit.

An alkylating agent of value against both hematologic malignancies and solid tumors.

The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.

More From BioPortfolio on "First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Searches Linking to this Trial